Sunday, January 15, 2017 9:36:06 PM
I want to see how much of a change immunopulse IL-12 can make in these exhausted phenotype percentages for CD8 TIL. We know that, based on interim phase 2 data, immunopulse IL-12 is able to convert 40% of predicted non-responders into responders (and some of these patients were actual non-responders to a variety of prior therapies including pembrolizumab). ARE THEY PRIMING THESE PATIENTS FOR PEMBROLIZUMAB BY ACTUALLY ELEVATING THEIR CTLA-4hi/PD-1hi CD8 TIL PHENOTYPE PERCENTAGES ABOVE 20%?
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM